Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4203 Comments
1887 Likes
1
Leo
Experienced Member
2 hours ago
Whoβs been watching this like me?
π 72
Reply
2
Yasine
Active Contributor
5 hours ago
Volume is concentrated in certain sectors, reflecting shifting investor priorities.
π 34
Reply
3
Ausar
Senior Contributor
1 day ago
Oh no, missed it! π
π 293
Reply
4
Sithara
Legendary User
1 day ago
As someone new, this wouldβve helped a lot.
π 278
Reply
5
Crisol
Legendary User
2 days ago
I agree, but donβt ask me why.
π 91
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.